Posted by Michael Wonder on 24 Mar 2021
Bayer receives approval for Vitrakvi in Japan
23 March 2021 - The Japanese marketing authorization of Vitrakvi follows the approval of the expanded use of FoundationOne CDx, a comprehensive genomic profiling test, in Japan for use as a companion diagnostic to identify patients with TRK fusion cancer who could benefit from treatment with Vitrakvi.
Bayer announced today that the Japanese Ministry of Health, Labor and Welfare has granted marketing authorization for larotrectinib, under the brand name Vitrakvi, for the treatment of neurotrophic yyrosine receptor kinase fusion-positive advanced or recurrent solid tumours.
